Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$4 Mln
P/E Ratio
--
P/B Ratio
1.2
Industry P/E
87.38
Debt to Equity
0
ROE
-2.22 %
ROCE
--
Div. Yield
0 %
Book Value
-0.35
EPS
--
CFO
$-191.71 Mln
EBITDA
$-226.79 Mln
Net Profit
$-405.33 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
ReShape Lifesciences (RSLS)
| -91.83 | -43.67 | -91.78 | -96.26 | -94.92 | -86.49 | -71.41 |
|
BSE Sensex*
| 2.52 | 3.37 | 6.44 | 8.80 | 12.18 | 20.37 | 11.43 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
ReShape Lifesciences (RSLS)
| -68.84 | -96.30 | -91.78 | -53.80 | -38.26 | 125.49 | -82.60 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 24.96 | 1,186.57 | -- | 0.74 | |
| 123.41 | 4,306.02 | 57.4 | 4.76 | |
| 94.61 | 5,591.89 | 46.38 | 8.89 | |
| 299.78 | 11,550.00 | 278.74 | 3.65 |
ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally... invasive long-term treatment of severe obesity and invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California. Read more
Executive Chair
Mr. Dan W. Gladney
Executive Chair
Mr. Dan W. Gladney
Headquarters
Irvine, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of ReShape Lifesciences Inc (RSLS) stood at $ 9 Mln as on 31-Mar-25
The share price of ReShape Lifesciences Inc (RSLS) is $0.37 (NASDAQ) as of 25-Apr-2025 16:28 EDT. ReShape Lifesciences Inc (RSLS) has given a return of -94.92% in the last 3 years.
ReShape Lifesciences Inc (RSLS) has a market capitalisation of $ 4 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of ReShape Lifesciences Inc (RSLS) is 1.20 times as on 25-Apr-2025, a 67% discount to its peers’ median range of 3.59 times.
Since, TTM earnings of ReShape Lifesciences Inc (RSLS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the ReShape Lifesciences Inc (RSLS) and enter the required number of quantities and click on buy to purchase the shares of ReShape Lifesciences Inc (RSLS).
ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California.
The CEO & director of Mr. Dan W. Gladney. is ReShape Lifesciences Inc (RSLS), and CFO & Sr. VP is Mr. Dan W. Gladney.
There is no promoter pledging in ReShape Lifesciences Inc (RSLS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,078
|
|
|
537
|
|
|
420
|
|
|
116
|
| ReShape Lifesciences Inc. (RSLS) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
-56.65
|
|
Net Margin(%)
|
-85.14
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of ReShape Lifesciences Inc (RSLS) was $0 Mln.
$-0.02
(
